The United Kingdom and the United States have hammered out a major bilateral deal that will ensure zero import taxes on UK drug exports being sold in the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has pledged to boost spending on medicines through the public health system. This pledge secures that import taxes on these vital goods will be held at nothing for a duration of three years.
This deal is in response to previous warnings to significantly raise tariffs on branded drug imports, with figures mentioned as high as one hundred percent.
"This deal between the United Kingdom bolsters the global environment for cutting-edge drugs and establishes much-needed fairness to U.S.–U.K. pharmaceutical trade," a release declared.
Economic Significance
Drugs constitute one of the the United Kingdom's most significant exports to the America, which is clearly the biggest market for leading companies like GSK and AstraZeneca.
Export figures reveal that in the one-year period to the end of last September, the UK sold medicines worth billions to the US. This amount accounted for a significant portion of all goods exports in that span.
"This deal safeguards employment, increases capital expenditure and facilitates the UK to emerge as a international leader for life sciences," the Business and Trade Secretary stated.
Detailed UK Commitments
The agreement includes several specific commitments from the British government:
- Price Threshold Increase: The UK will raise the affordability limit at which it considers new therapies to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a aim to increase total health service expenditure on drugs from 0.3% of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The percentage manufacturers must refund to the NHS to control costs will be limited at 15%. Previously, repayments were more than twenty percent.
Recent Tensions
The deal takes place against a protracted tension between the drug companies and the UK government over spending levels and regulatory access.
This friction were intensified by arguments that American consumers were charged significantly more for the same drugs than patients in the UK and Europe.
In recent months, several major pharmaceutical investments in the UK have been halted or abandoned, while substantial investments have been pledged toward US facilities.
The Science Minister stated that the NHS must spend more on medicines, noting that its expenditure on drugs had decreased as a percentage of its resources over the past decade.
